SCHEMBL25835917

SCHEMBL25835917

CCCNC(=O)CCOCCNC(=O)CCOCCNC(=O)CCOCCN(CCOCCC(=O)NCCOCCC(=O)NCCOCCC(=O)NCCC)C(=O)c1ccc(-c2nnc(SC)o2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
ALDH1A1 P00352 7/20 0.39
GAA P10253 1/20 0.39
CXCR4 P61073 1/20 0.38
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 5/20 0.35
KDM4E B2RXH2 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TP53 P04637 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 1/20 0.35
RXFP1 Q9HBX9 2/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PPARG P37231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26033158 0.99 POLB (0.40) POLBALDH1A1GAACXCR4LMNA
SCHEMBL25835923 0.86 POLB (0.33) POLBALDH1A1GAALMNAMAPT
SCHEMBL25836299 0.86 DRD2 (0.38) POLBCXCR4
SCHEMBL26032132 0.85 POLB (0.36) POLBALDH1A1LMNANPSR1MAPT
SCHEMBL26032119 0.85 POLB (0.36) POLBALDH1A1LMNANPSR1MAPT
SCHEMBL26036326 0.81 CXCR4 (0.34) POLBALDH1A1GAACXCR4LMNA
SCHEMBL26033618 0.79 DRD2 (0.36) POLB
SCHEMBL26032130 0.78 DRD2 (0.36)
SCHEMBL27384602 0.77 L3MBTL1 (0.34) POLBALDH1A1GAACXCR4LMNA
SCHEMBL26032111 0.77 HRH3 (0.40) ALDH1A1MAPTSMN1; SMN2TP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 POLB 302/4885ALDH1A1 1330/4885GAA 201/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 POLB 2117/4885ALDH1A1 2528/4885GAA 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.